Hogg K J, Gemmill J D, Burns J M, Lifson W K, Rae A P, Dunn F G, Hillis W S
University Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow.
Lancet. 1990 Feb 3;335(8684):254-8. doi: 10.1016/0140-6736(90)90069-h.
128 patients with acute myocardial infarction of duration 6 h or less were randomised in double-blind fashion to receive 30 U anistreplase over 5 min or 1.5 MU streptokinase over 1 h, both intravenously. Angiographic patency was assessed 90 min and 24 h from the start of therapy. 55% of patients who received anistreplase and 53% of patients who received streptokinase had patent infarct-related arteries (TIMI grade 2-3) at 90 min (95% CI 42-68% and 40-66%, respectively). At 24 h 81% and 87.5% of arteries were patent respectively (95% CI, 71-91% and 83.5-91.5%). Time to therapy had no significant effect on patency rates. There was one early reocclusion within 24 h in each treatment group and clinical evidence of reocclusion was recorded between 24 h and hospital discharge in a further 5 patients (streptokinase 3, anistreplase 2). With these regimens, therefore, anistreplase and streptokinase gave the same patency rates.
128例急性心肌梗死病程6小时或更短的患者被随机分为双盲组,分别接受静脉注射30万单位茴香酰化纤溶酶原链激酶激活剂(阿尼普酶),5分钟内注完,或150万单位链激酶,1小时内注完。在治疗开始后90分钟和24小时评估血管造影的通畅情况。接受阿尼普酶治疗的患者中,55%在90分钟时梗死相关动脉通畅(TIMI 2 - 3级),接受链激酶治疗的患者中这一比例为53%(95%置信区间分别为42 - 68%和40 - 66%)。在24小时时,动脉通畅率分别为81%和87.5%(95%置信区间分别为71 - 91%和83.5 - 91.5%)。治疗时间对通畅率无显著影响。每个治疗组在24小时内均有1例早期再闭塞,另有5例患者(链激酶组3例,阿尼普酶组2例)在24小时至出院期间有再闭塞的临床证据。因此,采用这些治疗方案时,阿尼普酶和链激酶的通畅率相同。